US Patent

US12544337 — Combinations of beta-lactam compounds and probenecid and uses thereof

Method of Use · Assigned to Iterum Therapeutics International Ltd · Expires 2039-12-23 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of bilayer tablets containing a beta-lactam compound and probenecid for treating or preventing a disease.

USPTO Abstract

The present disclosure relates to bilayer tablets comprising a second layer comprising a Î²-lactam compound or a pharmaceutically acceptable salt thereof; and a first layer comprising probenecid or a pharmaceutically acceptable salt thereof. The present disclosure also relates to methods of treating or preventing a disease using the bilayer tablets.

Drugs covered by this patent

Col-Probenecid (probenecid) · Pfizer Inc.

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4026`	—	Col-Probenecid

Patent Metadata

Patent number: US12544337
Jurisdiction: US
Classification: Method of Use
Expires: 2039-12-23
Drug substance claim: No
Drug product claim: Yes
Assignee: Iterum Therapeutics International Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.